BioXcel Therapeutics Files Definitive Proxy Statement

TL;DR

BioXcel Proxy Statement is IN: Vote on directors & auditors for Jan 28 meeting.

AI Summary

BioXcel Therapeutics, Inc. filed its definitive proxy statement on December 30, 2024, for its annual meeting of stockholders scheduled for January 28, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership, executive pay, and voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new financial risks.

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — Registrant
• 20250128 (date) — Annual Meeting Date
• 20241230 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — he Company's common stock, par value of $0.001 per share (the "Common Stock"), at the
• $1.00 — n Stock maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listi
• $0.3901 — Capital Market on December 17, 2024 was $0.3901 per share and, over the prior 52 weeks,
• $0.38 — Company's Common Stock has ranged from $0.38 to $4.04 per share. As previously dis
• $4.04 — s Common Stock has ranged from $0.38 to $4.04 per share. As previously disclosed, o

Filing Documents

• tm2431290-2_def14a.htm (DEF 14A) — 240KB
• lg_bioxceltherapeutreg-4c.jpg (GRAPHIC) — 13KB
• px_24biopxy01pg01-bw.jpg (GRAPHIC) — 210KB
• px_24biopxy01pg02-bw.jpg (GRAPHIC) — 187KB
• sg_javierrodriguez-bw.jpg (GRAPHIC) — 6KB
• 0001104659-24-132508.txt ( ) — 753KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 13 ADDITIONAL INFORMATION 15 OTHER MATTERS 17 APPENDIX A A-1 i TABLE OF CONTENTS BIOXCEL THERAPEUTICS, INC. PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS GENERAL INFORMATION ABOUT THE SPECIAL MEETING Our Board of Directors (the "Board") solicits your proxy on our behalf for the Special Meeting of Stockholders (the "Special Meeting") and at any postponement or adjournment of the Special Meeting for the purposes set forth in this proxy statement (the "Proxy Statement") and the accompanying Notice of Special Meeting of Stockholders (the "Notice"). The Special Meeting will be held virtually via live webcast, on Tuesday, January 28, 2025 at 9:00 a.m. local time. You will be able to attend the Special Meeting online and submit your questions during the meeting by visiting www.shareholdermeeting.com/BTAI2025SM and entering your 16-digit control number included on your proxy card or in the instructions that accompanied your proxy materials. If you lose your 16-digit control number, you may join the Special Meeting as a "Guest" but you will not be able to vote or ask questions. This Proxy Statement is first being sent to stockholders on or about December 30, 2024. Unless we state otherwise or the context otherwise requires, references in this Proxy Statement to "we," "our," "us," or the "Company" are to BioXcel Therapeutics, Inc., a Delaware corporation. Purpose of the Special Meeting At the Special Meeting, stockholders will act upon the proposals described in this Proxy Statement. In addition, we will consider any other matters that are properly presented for a vote at the Special Meeting. We are not aware of any other matters to be submitted for consideration at the Special Meeting. If any other matters are properly presented for a vote at the Special Meeting, the persons named in the proxy, who are officers of the Company, have the authority in their discretion to vot

View Full Filing

View this DEF 14A filing on SEC EDGAR